Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entera Bio Ltd.ENTX · Entity 5464 | Chief of R&D | August 07, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entera Bio Ltd.
Report date August 07, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07 | Direct | 180,000 |
Reported balance
After 2026-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 180,000 · Balance 180,000 F1: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 7, 2026 20:19 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001178913-26-003951 · zk2635793.xml · derivative · entry 1 Burshtein Gregory · CIK 0002026002 · Chief of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 180,000 shares Expires 2036-05-07 F1 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan). Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:26 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 87,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-002462 · ownership.xml · nonDerivative · entry 1 Burshtein Gregory · CIK 0002026002 · Chief of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,033 F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:35 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001178913-25-002412 · ownership.xml · derivative · entry 2 Burshtein Gregory · CIK 0002026002 · Chief of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 200,000 shares Expires 2035-04-28 F2 · derivative.exercise_date: This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:35 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 26,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-25-002412 · ownership.xml · nonDerivative · entry 1 Burshtein Gregory · CIK 0002026002 · Chief of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,442 F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.